Conclusion of a non-exclusive rebate agreement under Section 130a(8) SGB V for the active substance Pomalidomide, ATC L04AX06, for the period 01/06/2026 - 31/05/2028 (plus option to extend once by 12 months)

Summary

The tender concerns the conclusion of a non-exclusive rebate agreement for medicines containing Pomalidomide (ATC L04AX06) for the period 01/06/2026 to 31/05/2028, with an option to extend once by 12 months. It is an open accession model: interested pharmaceutical companies may join the contract if they submit the required documents by email on time. The exact qualification and compliance requirements must be checked in the tender documents.